HIK Insider Trading

Insider Ownership Percentage: 30.72%
Insider Buying (Last 12 Months): £27,300
Insider Selling (Last 12 Months): GBX 0

Hikma Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Hikma Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Hikma Pharmaceuticals Share Price & Price History

Current Price: GBX 1,777
Price Change: Price Increase of +3 (0.17%)
As of 04/18/2024 08:08 AM ET

This chart shows the closing price history over time for HIK up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Hikma Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/6/2023Douglas HurtInsiderBuy1,500GBX 1,820£27,300
1/17/2023Deneen VojtaInsiderBuy1,000GBX 1,703£17,030
3/14/2022Sigurdur OlafssonInsiderSell27,498GBX 1,988£546,660.24
3/3/2022Douglas HurtInsiderBuy1,500GBX 1,954£29,310
See Full Table

SEC Filings (Institutional Ownership Changes) for Hikma Pharmaceuticals (LON:HIK)

39.27% of Hikma Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Hikma Pharmaceuticals logo
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
Read More on Hikma Pharmaceuticals

Today's Range

Now: GBX 1,777
Low: 1,770
High: 1,792

50 Day Range

MA: GBX 1,906.93
Low: 1,774
High: 2,083

52 Week Range

Now: GBX 1,777
Low: 1,711
High: 2,222

Volume

663,229 shs

Average Volume

428,216 shs

Market Capitalization

£3.94 billion

P/E Ratio

2,652.24

Dividend Yield

3.03%

Beta

0.45

Who are the company insiders with the largest holdings of Hikma Pharmaceuticals?

Hikma Pharmaceuticals' top insider shareholders include:
  1. Deneen Vojta (Insider)
  2. Douglas Hurt (Insider)
Learn More about top insider investors at Hikma Pharmaceuticals.